International Markets
Out-Licensing Strategy
Our out-licensing activities are driven by our robust manufacturing capabilities, strict quality standards, and our strategic vision to expand our portfolio into international markets.
Portfolio Priorities
- High market-potential products
- Formulations aligned with international regulatory requirements
- Opportunities across strategic therapeutic segments
59
Country
93
Licenses Received
Biem Worldwide
Products in Our Portfolio
Licensed Products
High-potential products in the market.
CTD Dosier Ready Products
Licensible full dosier content.
Projects Under Development
R&D portfolio, reformulations or new technologies.
Business Models
License Agreements
Transfer of commercial rights for specific countries.
Technology Transfer
Sharing of manufacturing know-how and quality processes.
Shared R&D Projects
Development of new formulations or product variants.
Work With Us
International Quality Standards
Compliance with GMP, ISO, and similar standards.
Strong Manufacturing Capability
Advanced manufacturing capacity through Biem’s production facility in Çerkezköy, Tekirdağ.
Transparent and Flexible Collaboration Approach
Project-by-project evaluation based on mutual benefit.